Considering our observation of greater interday glycemic variability with once-weekly GH treatment than with once-daily GH treatment, CGM-based monitoring may be crucial, particularly in individuals with diabetes or those with a high risk of cardiovascular disease. This evidence concerns the gene GH1 and diabetes mellitus.